Shots:  The US FDA has granted BLA approval of Nypozi (TX01), biosimilar version of Amgen’s Neupogen  Nypozi (TX01) is intended to reduce the incidence of infection among patients having non-myeloid malignancies undergoing chemotherapy that may reduce neutrophil count  The company’s Nypozi was introduced across Canada in Jan 2024  Ref: Tanvex BioPharma | Image: Tanvex BioPharma | Press Release…